Delving into the Latest Updates on Polatuzumab Vedotin-Piiq with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

anti-CD79b-VC-MMAE, polatuzumab vedotin, Polatuzumab Vedotin(Genetical Recombination)

+ [16]

Target

CD79B x Tubulin

Action

modulators, inhibitors

Mechanism

CD79B modulators(B-cell antigen receptor complex-associated protein beta chain modulators), Tubulin inhibitors

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication

Large B-cell lymphomaHigh grade B-cell lymphomaDiffuse large B-cell lymphoma refractory+ [29]

Inactive Indication

Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Originator Organization

GeneTech, Inc.

Active Organization

Hoffmann-La Roche, Inc.Roche Pharma AG

F. Hoffmann-La Roche Ltd.

+ [9]

Inactive Organization

Roche Products Ltd.

License Organization

Seagen, Inc.

Genentech, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (10 Jun 2019),

Diffuse Large B-Cell Lymphoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Sequence Code 31655L

Source: *****

Sequence Code 9976257H

Source: *****

This phase II trial tests how well polatuzumab vedotin, mosunetuzumab, and acalabrutinib work in treating patients with mantle cell lymphoma. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug called monomethyl auristatin E. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD79B receptors, and delivers monomethyl auristatin E to kill them. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving polatuzumab vedotin, mosunetuzumab, and acalabrutinib together may be an effective treatment option for patients with mantle cell lymphoma.

Start Date01 Mar 2027

Sponsor / Collaborator

University of Washington

[+1]

NCT07714421

/ Not yet recruitingPhase 1IIT

A Phase I Study of Single Agent Epcoritamab Followed by Epcoritamab Plus Pola-R-Mini-CHP for Elderly/Unfit Patients With Previously Untreated DLBCL

This phase I trial tests the safety, side effects and best dose of epcoritamab alone and epcoritamab with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R- mini-CHP) for the treatment of diffuse large B cell lymphoma (DLBCL) in elderly or unfit patients. Epcoritamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a chemotherapy drug, called monomethyl auristatin E. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as B-cell receptors, and delivers monomethyl auristatin E to kill them. Rituximab is a monoclonal antibody. It binds to a protein called cluster of differentiation antigen 20 (CD20), which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Epcoritamab alone and epcoritamab with pola-R-mini-CHP may be safe, tolerable and/or effective in treating DLBCL in elderly or unfit patients.

Start Date08 Dec 2026

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+1]

NCT07502872

/ Not yet recruitingPhase 2IIT

TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).

Start Date01 Nov 2026

Sponsor / Collaborator

Brown University

[+3]

100 Clinical Results associated with Polatuzumab Vedotin-Piiq

Login to view more data

100 Translational Medicine associated with Polatuzumab Vedotin-Piiq

Login to view more data

100 Patents (Medical) associated with Polatuzumab Vedotin-Piiq

Login to view more data

808

Literatures (Medical) associated with Polatuzumab Vedotin-Piiq

31 Dec 2026·Human Vaccines & Immunotherapeutics

Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes

Review

Author: Shouse, Geoffrey

Mosunetuzumab is a bispecific antibody targeting CD20 x CD3 re-directing T cells to target and destroy CD20-positive B cells. T-cell-based therapies including bispecific antibodies have revolutionized B-cell NHL treatment. Mosunetuzumab is approved for follicular lymphoma with at least 2 prior lines of therapy. There are also NCCN recommendations for its use in diffuse large B-cell lymphoma and in combination with polatuzumab vedotin in relapsed/refractory mantle cell lymphoma with prior BTK inhibitor therapy. Published trials show low rates of severe CRS and support outpatient administration in appropriate settings. Utilizing a search of PubMed, conference abstracts, and clinicaltrials.gov between 2020 and 2026, prospective trial data as well as retrospective real-world evidence and ongoing studies were included for a more complete picture of available data. This review summarizes the molecular design, mechanism of action, clinical efficacy, and safety of mosunetuzumab, an agent representative of immunotherapeutic advancement in lymphoma.

01 Nov 2026·Blood neoplasia

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP– but not Pola-R-CHP–treated patients with DLBCL

Article

Author: Yan, Mark ; Herrera, Alex F ; Jiang, Yanwen ; Izutsu, Koji ; Bolen, Christopher R ; Staber, Philipp B ; Tucci, Alessandra ; Lenz, Georg ; Harris, Will ; Lu, Kai ; Jardin, Fabrice ; Hou, Jing-Zhou ; Hirata, Jamie ; Morschhauser, Franck ; Belada, David ; Hatzi, Katerina ; Burke, John M ; Hawkes, Eliza A ; Le Gouill, Steven ; Flowers, Christopher R ; Trněný, Marek ; Lee, Calvin

The influence of the tumor immune microenvironment (TME) on therapeutic efficacy remains unclear in diffuse large B-cell lymphoma, particularly for regimens incorporating antibody-drug conjugates (ADCs). We aimed to define the key lymphoma microenvironment factors associated with clinical outcomes in patients treated with anti-CD20 (rituximab or obinutuzumab) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; anti-CD20 + CHOP) and to understand how treatment with a modified, ADC-containing chemoimmunotherapy regimen alters the influence of the pretreatment immune landscape on clinical outcome. We evaluated associations between TME composition and clinical outcomes in a harmonized data set of 1279 patients treated with either anti-CD20 + CHOP or a modified regimen of anti-CD20 + CHOP containing polatuzumab vedotin (Pola-R-CHP) across 3 clinical studies. We found that low enrichment of M1-like macrophages was consistently associated with inferior overall and progression-free survival in anti-CD20 + CHOP-treated patients, suggesting that these macrophages may facilitate antibody-mediated efficacy. In contrast, outcomes in polatuzumab vedotin-treated patients were independent of macrophage levels, supporting a mechanism of action driven primarily by ADC payload cytotoxicity. Other immune signatures that predicted outcome with anti-CD20 + CHOP treatment were also not prognostic with Pola-R-CHP treatment. Our results indicate that ADCs may provide therapeutic benefit to patients with unfavorable immune microenvironments. These trials were registered at www.clinicaltrials.gov as #NCT01287741, #NCT00486759, and #NCT03274492.

03 Oct 2026·Expert Opinion On Drug Safety

Adverse event profiles of four monomethyl auristatin E-conjugated antibody drug conjugates: a disproportionality analysis based on the US FDA adverse event reporting system (FAERS) database

Article

Author: Hirota, Takeshi ; Uchida, Mayako ; Ieiri, Ichiro ; Doi, Yohei

BACKGROUND:

Antibody-drug conjugates (ADCs) with monomethyl auristatin E (MMAE) have recently become prevalent in cancer treatment. This study aimed to comprehensively examine the adverse events (AEs) associated with regulatory-approved MMAE-conjugated ADCs using the FDA Adverse Event Reporting System (FAERS).

RESEARCH DESIGN AND METHODS:

A disproportionality analysis of reports from July 2011 to September 2024 was conducted to detect AE signals in adult patients with cancer receiving any of the four MMAE-conjugated ADCs (brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin, and tisotumab vedotin) using reporting odds ratio and information component.

RESULTS:

FAERS yielded 12,655 reported cases with 4,958 drug-AE pairs. Positive signals observed across the four MMAE-ADCs included 'blood and lymphatic system disorders' and 'metabolism and nutrition disorders' at the system organ class, and anemia, febrile neutropenia, hypokalemia, peripheral neuropathy, and pneumonitis for individual AEs, with 54 other overlapping AEs shared by at least three of the ADCs.

CONCLUSIONS:

FAERS analysis revealed overlapping safety signals in MMAE-conjugated ADCs. Although further research is necessary to clarify causal relationships, our findings provide a basis for understanding the characteristics of possible AEs in MMAE-ADCs, aiding clinical decision-making for patient safety management.

197

News (Medical) associated with Polatuzumab Vedotin-Piiq

02 Nov 2026

·www.fresenius.com

Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

Contact Steffi Kim T: +49 (0) 175 32 84 722 steffi.kim@fresenius.com Documents Text as PDF document (PDF, 145 KB) Exclusive option rights for up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius’ portfolio from 29 marketed and pipeline molecules today to up to 66 in the next decade, addressing more than €370 billion in originator sales; the largest development agreement announced in the biosimilars industry to date. Agreement gives Fresenius full strategic flexibility to select and advance biosimilar candidates to develop, against its established selection criteria, while retaining full commercialization economics of products under the agreement. Fresenius will determine the long-term manufacturing strategy for each candidate, with optionality to leverage the mAbxience network, wholly owned since October 2026. The next-generation portfolio spans 13 therapeutic areas and multiple biologic technologies, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) today announced that it has entered an exclusive development agreement with WuXi Biologics (2269.HK), a leading global contract organization for research, development and manufacturing. WuXi Biologics brings proven large-scale biologics development and manufacturing capability, a track record across monoclonal and bispecific antibodies and antibody-drug conjugates, and a worldwide network spanning Europe, the United States, China and Singapore. The agreement significantly expands and accelerates Fresenius’ biosimilars pipeline while preserving strategic flexibility and disciplined capital allocation. It provides access to a scalable pathway to increase the portfolio from 29 marketed and pipeline molecules today to up to 66 molecules, addressing more than €370 billion in originator list-price-based-sales, extending Biopharma growth in the long term beyond its 2030 ambition. The agreement provides Fresenius with exclusive access to up to 37 identified biosimilar candidates over the next decade, making it the largest development agreement announced in the biosimilars industry to date. Development programs will be selected and advanced against Fresenius’ established selection criteria, based on market attractiveness, development risk, and expected returns. Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product under the agreement. Michael Sen, Chief Executive Officer of Fresenius, said: “We are doubling down on our Biopharma business. With this agreement we are gaining access to development capabilities in a market where speed and scale are of the essence. It provides a disciplined, scalable way to potentially triple our portfolio while retaining economic ownership, strategic control and the flexibility to allocate capital to the most compelling opportunities. Combined with the full ownership of mAbxience, this fuels our Biopharma growth well beyond 2030.” The next-generation portfolio is expected to span 13 therapeutic areas, including expanding into neurology, nephrology and cardiopulmonary, while further strengthening Fresenius’ established positions in oncology, immunology, and gastroenterology. It will encompass multiple biologic technologies, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Initial development is expected to focus on polatuzumab vedotin, an antibody-drug conjugate for the treatment of diffuse large B-cell lymphoma, and teprotumumab, a monoclonal antibody for the treatment of thyroid eye disease. The agreement forms part of a balanced pipeline expansion strategy through internal R&D, targeted collaboration, and selective in-licensing. It gives Fresenius privileged access to the rapidly advancing biotech landscape worldwide and combines this with Fresenius’ global manufacturing and commercialization network. Development activities are expected to be conducted using WuXi Biologics’ global network. Building on the recent acquisition of Spain-headquartered mAbxience, the agreement significantly expands the funnel of potential development candidates for Fresenius’ wholly owned platform, enabling greater value capture across the development, manufacturing and commercialization value chain. Small-scale bioreactors used during biosimilar development to evaluate and optimize cell-culture conditions and bioprocess parameters, generating data to support molecule characterization and subsequent scale-up. Download Scientific visualization of a monoclonal antibody binding to a specific target on a cell surface, illustrating the targeted mechanism of action of antibody-based biologic medicines. Download Fresenius Headquarter in Bad Homburg, Germany. Download Image (JPEG 4066KB) Financial Considerations Fresenius’ full-year 2026 guidance remains unchanged, and the company confirms the 2030 Biopharma ambition announced in December 2025 of – approximately doubling Biopharma revenue compared with 2025 at an EBIT margin of around 20% – which relates to the existing marketed and late-stage portfolio. The agreement is additive, expanding the opportunity beyond 2030, and, as a result, Fresenius expects to raise its long-term Biopharma ambitions significantly. Under the terms of the agreement, Fresenius will compensate WuXi Biologics on a fee-for-service basis for each biosimilar candidate that Fresenius selects for development. Research and development investment scales only as selected programs progress, with each option exercised against Fresenius’ established selection criteria (market attractiveness, development risk, and expected returns). Fresenius will determine the long-term manufacturing strategy for each biosimilar candidate, including the potential progressive transfer of selected products to mAbxience. Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product under the agreement. As selected candidates advance, Biopharma research and development expenditure and profitability will correspondingly reflect the increased level of investment during the development phase, ahead of future revenue and profitability growth. The agreement fits within Fresenius’ unchanged financial framework, with continued priority on a strong balance sheet and further deleveraging; it is funded from operating cash flow and requires no new financing. Fresenius is rated BBB with a positive outlook by S&P, Baa3 with a stable outlook by Moody’s, and BBB- with a positive outlook by Fitch. Related Publications The 1 October 2026 announcement of Fresenius' acquisition of the remaining 45% of mAbxience is available here . The 31 March 2022 announcement of Fresenius Kabi's acquisition of a 55% majority stake in mAbxience is available here , and the 1 August 2022 completion announcement here . The Biopharma 'Meet the Management' presentation of 15 December 2025 is available here

AcquisitionLicense out/inADC

02 Nov 2026

·www.pharmamanufacturing.com

Fresenius, WuXi Biologics ink exclusive agreement to develop biosimilars

Fresenius, a Germany-based healthcare company with a biopharmaceutical business, has entered an exclusive development agreement with WuXi Biologics, a China-headquartered contract research, development and manufacturing organization (CRDMO), to expand its biosimilars pipeline. The agreement gives Fresenius exclusive option rights to up to 37 biosimilar candidates, potentially increasing its marketed and pipeline portfolio from 29 molecules to as many as 66 over the next decade. The candidates address originator products with more than €370 billion in combined sales based on list prices, according to Fresenius. The company will select which programs to advance using criteria that include market attractiveness, development risk and expected returns. Fresenius will retain exclusive global commercialization rights, including marketing authorizations and the full economics of products it takes through development. The portfolio is expected to span 13 therapeutic areas, including oncology, immunology, gastroenterology, neurology, nephrology, and cardiopulmonary conditions. It will include monoclonal and bispecific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. Initial development is expected to focus on polatuzumab vedotin, an ADC for diffuse large B-cell lymphoma, and teprotumumab, a monoclonal antibody for thyroid eye disease. Under the agreement, WuXi Biologics will provide development services for candidates selected by Fresenius, who will pay for each program on a fee-for-service basis, with research and development investment increasing as individual candidates progress. Development activities are expected to use WuXi Biologics’ global network, which spans Europe, the United States, China and Singapore. Fresenius will determine the long-term manufacturing strategy for each candidate, including the potential transfer of selected products to mAbxience, its wholly owned biosimilars development and manufacturing platform. The agreement gives Fresenius flexibility to use its own manufacturing network as programs advance while retaining control over commercialization. The agreement is additive to Fresenius’ existing 2030 biopharma ambition, which calls for approximately doubling biopharma revenue compared with 2025 at an earnings-before-interest-and-taxes margin of about 20%. The company said the new pipeline opportunities are expected to support growth beyond 2030. Its full-year 2026 financial guidance remains unchanged. Development spending will increase as selected programs advance, with the agreement funded through operating cash flow. The deal follows Fresenius’ acquisition of the remaining 45% stake in mAbxience , announced Oct. 1, which gave it full ownership of the biosimilars developer and manufacturer. Fresenius acquired a 55% majority stake in 2022. The business operates three multi-product drug substance manufacturing facilities in Spain and Latin America, supporting biosimilar monoclonal antibody production and contract manufacturing services. Full ownership gives Fresenius greater control over manufacturing capacity, investment decisions, and the platform’s development and commercialization strategy.

AcquisitionLicense out/inADC

06 Oct 2026

·www.fiercepharma.com

AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy

AbbVie and Genmab are touting a much-anticipated first-line win for Epkinly as a combination treatment for diffuse large B-cell lymphoma (DLBCL), teeing up a potential change to the standard of care and fierce competition with Roche’s first-line Polivy regimen. The drugmakers tested their bispecific antibody, also known as epcoritamab, in combination with the lymphoma standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisone (R-CHOP). Together, Epkinly plus R-CHOP reduced the risk of disease progression or death by 51% in newly diagnosed patients with DLBCL compared with R-CHOP alone, according to topline results from the Epcore DLBCL-2 phase 3 trial. The study met its primary progression-free survival endpoint in patients with International Prognostic Index scores of 3 to 5, while the combination also reduced the risk of progression or death by 51% across the broader group of patients with IPI scores of 2 to 5. AbbVie and Genmab said the combination was generally well tolerated and its safety profile was consistent with previously reported safety data for Epkinly and R-CHOP. Detailed results will be submitted for presentation at a future medical meeting. "DLBCL is an aggressive disease and the need to advance treatment options is critical. These positive topline results suggest that epcoritamab combined with R-CHOP could offer a potential new standard of care in newly diagnosed DLBCL patients," said Daejin Abidoye, M.D., vice president and therapeutic area head of oncology, solid tumors and hematology at AbbVie. The 51% drop in the risk of progression or death is “highly relevant to everyday practice. These results have the potential to be practice-changing," said Gilles Salles, M.D., Ph.D., chief of lymphoma service at Memorial Sloan Kettering. Salles was an investigator on both the Epcore DLBCL-2 trial and the landmark study that established R-CHOP as a standard of care nearly 25 years ago. A bispecific antibody, Epkinly, is given by subcutaneous injection and works by redirecting T cells to attack B cells in B-cell lymphoma. It’s currently approved under the FDA's accelerated approval pathway as a third-line therapy for DLBCL after patients have received at least two prior lines of systemic therapy. Epkinly, marketed as Tepkinly in Europe and some other markets, brought in $312 million in global sales during the first half of 2026 across its approved indications. An estimated 25,000 cases of DLBCL are diagnosed each year in the U.S., representing a substantial market should the Epkinly-R-CHOP combination secure a first-line approval. TD Cowen analysts have said a positive first-line readout could give investors confidence that Epkinly can reach $3 billion in peak sales. Such an approval would place Epkinly in a heated rivalry with Roche’s blockbuster Polivy, an infused antibody-drug conjugate approved in 2023 as part of a first-line combination with rituximab, cyclophosphamide, doxorubicin and prednisone, or R-CHP. In that regimen, Polivy takes the place of vincristine in R-CHOP. Polivy generated 808 million Swiss francs (about $972 million) in global sales in the first half of 2026. The topline efficacy figures also set up a closely watched comparison with Polivy, though the results come from separate trials and cannot be directly compared. Epkinly plus R-CHOP posted a hazard ratio of 0.49 for disease progression or death in Epcore DLBCL-2. In Roche’s registrational Polarix study, Polivy plus R-CHP recorded a hazard ratio of 0.73, reflecting a 27% reduction in the risk of progression, relapse or death compared with R-CHOP. The studies also differed somewhat in how their patient populations were analyzed. Epcore DLBCL-2 enrolled patients with IPI scores of 2 to 5, while its primary progression-free survival endpoint was assessed in patients with scores of 3 to 5. Polarix enrolled patients with IPI scores ranging from 2 to 5. Roche’s Columvi, which works through the same CD20xCD3 bispecific mechanism as Epkinly, is also gunning for earlier placement in the DLBCL treatment lineup. Columvi is approved under the FDA's accelerated approval pathway for third-line or later DLBCL. But last year, the FDA rejected Roche’s bid for a second-line combination with GemOx, concluding that data from the phase 3 Starglo trial did not provide sufficient evidence to support the proposed indication in the U.S. patient population. For AbbVie and Genmab, the latest readout is a welcome relief after a surprise phase 3 setback for Epkinly as a monotherapy in the Epcore DLBCL-1 trial earlier this year. While Epkinly improved progression-free survival, the study failed to show a statistically significant improvement in overall survival, which was the sole U.S. primary endpoint. Hope rebounded in late June when AbbVie and Genmab announced a positive phase 3 readout for Epkinly plus lenalidomide in patients with relapsed or refractory DLBCL who had received at least one prior line of treatment. The combination significantly improved progression-free survival compared with R-GemOx in the Epcore DLBCL-4 trial. Neither the first-line Epkinly-R-CHOP regimen nor the Epkinly-lenalidomide regimen is approved for these uses. The drugmakers said they would work with global regulators to determine the next steps.

100 Deals associated with Polatuzumab Vedotin-Piiq

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10761	Polatuzumab Vedotin-Piiq	L01FX14 L04AG L01XC	DB12240

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Large B-cell lymphoma	Japan	Chugai Pharmaceutical Co., Ltd.	23 Mar 2026
High grade B-cell lymphoma	United States	Genentech, Inc.	18 Mar 2026
Diffuse large B-cell lymphoma refractory	China	Roche China Holding Ltd.	10 Mar 2026
Refractory Lymphoma	Canada	Hoffmann-La Roche Ltd.	09 Jul 2020
Diffuse large B-cell lymphoma recurrent	European Union	Roche Registration GmbH	16 Jan 2020
Diffuse large B-cell lymphoma recurrent	Iceland	Roche Registration GmbH	16 Jan 2020
Diffuse large B-cell lymphoma recurrent	Liechtenstein	Roche Registration GmbH	16 Jan 2020
Diffuse large B-cell lymphoma recurrent	Norway	Roche Registration GmbH	16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	European Union	Roche Registration GmbH	16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Iceland	Roche Registration GmbH	16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Liechtenstein	Roche Registration GmbH	16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Norway	Roche Registration GmbH	16 Jan 2020
Diffuse Large B-Cell Lymphoma	United States	Genentech, Inc.	10 Jun 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	United States	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	China	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	Japan	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	Argentina	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	Brazil	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	Canada	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	Israel	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	Mexico	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	New Zealand	Hoffmann-La Roche, Inc.	25 Apr 2022
Refractory Aggressive Non-Hodgkin Lymphoma	Phase 3	Peru	Hoffmann-La Roche, Inc.	25 Apr 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05410418 (CTgov)	Phase 2	Follicular Lymphoma	34	Mosunetuzumab+Polatuzumab vedotin	kghywhnwyl = kruaoapnvy cafnswghzn (fitavlutqp, svwjgxmadq - pwulvjtzyz) View more	-	28 Oct 2026
NCT05169658 (Pubmed \| J Clin Oncol)	Phase 1	Indolent B-Cell Non-Hodgkin Lymphoma	42	ObinutuzumabMosunetuzumabPolatuzumab vedotin + ObinutuzumabMosunetuzumabPolatuzumab vedotin + ObinutuzumabMosunetuzumabPolatuzumab vedotin	bzrctixcrj(qxbhfmjkut) = cgfclqkiqp srpuyninnd (nofzqidmqg ) View more	Positive	20 Sep 2026
NCT04182204 (POLARGO, Pubmed \| J Clin Oncol)	Phase 3	Diffuse large B-cell lymphoma recurrent	255	Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin	haxbemeqbn(qrkdnepbgp) = heqkfzfasd lelbzcbddp (xnoughkzib, 13.3 - NE) View more	Positive	01 Sep 2026
				Rituximab, Gemcitabine, and Oxaliplatin	haxbemeqbn(qrkdnepbgp) = drksdrsrgf lelbzcbddp (xnoughkzib, 8.9 - 15.8) View more
POLARIX (ASCO2026)	Not Applicable	High grade B-cell lymphoma	19,327	Pola-R-CHP	vscbowxnme(yfaflmxayz) = izowgiqdbf zgwlqkinxi (ifwzlltpfz ) View more	Positive	29 May 2026
				R-CHOP	vscbowxnme(yfaflmxayz) = yhxutgedse zgwlqkinxi (ifwzlltpfz ) View more
NCT05169658 (RESPONSE-ADAPTED TREATMENT WITH MOSUNETUZUMAB, CTgov)	Phase 2	Follicular Lymphoma \| Indolent B-Cell Non-Hodgkin Lymphoma \| Marginal Zone B-Cell Lymphoma	42	FDG-Positron Emission Tomography+Mosunetuzumab+Polatuzumab Vedotin+Obinutuzumab	brdjtllwdz = npshkdtwxw jtxqwdbwaa (cqyneqrchq, brmzxytlxv - yernvivvzb) View more	-	13 May 2026
EHA2026	Not Applicable	Diffuse Large B-Cell Lymphoma	177	Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) (Diffuse Large B-Cell Lymphoma (DLBCL))	twejehwchb(rfwcwecxzs) = shxhgjzisr hercmdmqfu (zcnltyehia )	Positive	12 May 2026
				Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) (High transferrin (≥2.18 g/L))	twejehwchb(rfwcwecxzs) = ecklveccdo hercmdmqfu (zcnltyehia )
NCT03274492 (POLARIX, EHA2026)	Phase 3	Diffuse Large B-Cell Lymphoma First line Double-Expressor	115	Polatuzumab vedotin plus R-CHP (Pola-R-CHP)	nilvobbhcu(eaeajwlhpr) = xufktbsrge vuibgviund (qpkdxwpsqt )	Positive	12 May 2026
				Tucidinostat + R-CHOP (Tuci-R-CHOP)	nilvobbhcu(eaeajwlhpr) = csxayvvghs vuibgviund (qpkdxwpsqt )
EHA2026	Not Applicable	Large B-cell lymphoma	625	Polatuzumab Vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine Sulfate + Sphingosine-1-Phosphate Lyase Inhibitor + Prednisone	ohhikxotjv(xygcoyxzin) = cbpxfptfdr nydnehlhch (cncysbomtl ) View more	Positive	12 May 2026
				Rituximab + Cyclophosphamide + Doxorubicin + Vincristine Sulfate + Sphingosine-1-Phosphate Lyase Inhibitor + Prednisone	ohhikxotjv(xygcoyxzin) = jkappjyyfd nydnehlhch (cncysbomtl ) View more
EHA2026	Not Applicable	Diffuse Large B-Cell Lymphoma First line	103	Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP)	wyksttwfgy(mlsolbsoqc) = hfcmlmadfd kgdxmxbrky (pyciburrxm ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Diffuse Large B-Cell Lymphoma First line	437	Polatuzumab Vedotin plus R-CHP	bjlmlasmzo(odwjodtufm) = yfoysfybla cvhvclzdbu (coraartgnz ) View more	Positive	12 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.